HOME > BUSINESS
BUSINESS
- Keytruda Remains No. 1 in November Japan Drug Ranking: Encise
December 6, 2019
- Boston Biomedical Ties Up with 3 Institutions in Oncology Research
December 5, 2019
- With Audentes Buyout, Astellas Poised to Position “Genetic Regulation” as 5th Biz Pillar
December 4, 2019
- Original Maker Recalls Nizatidine over Carcinogen Risks
December 4, 2019
- Vyvanse Now Available in Japan 6 Months after Listing
December 4, 2019
- Astellas, Seattle Genetics Join Hands with US Merck for ADC/Keytruda Combo
December 4, 2019
- Takeda Launches Zafatek 25 mg for Patients with Renal Dysfunction
December 4, 2019
- Shire Rolls Out Kit Version of Advate IV in Japan
December 4, 2019
- Idelvion’s 3500 IU Vials Available in Japan: CSL Behring
December 4, 2019
- Lenvima’s Add’l Thyroid Cancer Use Accepted for Chinese Regulatory Review
December 3, 2019
- Zykadia’s Film-Coated Tablets Now Available
December 3, 2019
- Full Showdown Starts as Mylan’s Nesp Biosimilar Reaches Market
December 3, 2019
- Crysvita’s Japan Launch Set for Dec. 6: Kyowa Kirin
December 3, 2019
- Chugai Completes Transfer of 3 Dermatology Products to Maruho
December 3, 2019
- Astellas to Buy Gene Therapy Player Audentes for US$3 Billion
December 3, 2019
- Shionogi Introduces AI Chatbot for Xofluza Inquiries from Medical Professionals
December 3, 2019
- Satralizumab Reduces Risk of NMOSD Relapses: Chugai
December 2, 2019
- JT’s Enarodustat 4th HIF-PH Inhibitor Filed in Japan
December 2, 2019
- Boehringer Innovation Chief Touts R&D Efforts on Undruggable Cancer Targets
December 2, 2019
- Santen Starts Voluntary Recall of Pivalephrine
December 2, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
